Back
Speaker illustration

Doctor Corina Becker

Bayer AG, Wuppertal (Germany)

Presentations

Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects

Event: ESC Congress 2020

Topic: Cardiovascular Pharmacotherapy

Session: Pharmacology and Pharmacotherapy ePosters

Access
Like
Thumbnail

Pharmacodynamic interaction study of a long-acting nitrate co-administered with vericiguat in patients with stable coronary artery disease

Event: Heart Failure 2019

Topic: Cardiovascular Pharmacotherapy, Other

Session: Pharmacology and Pharmacotherapy

Access
Like
Thumbnail

Pharmacodynamic and pharmacokinetic interaction profile of vericiguat

Event: Heart Failure 2019

Topic: Cardiovascular Pharmacotherapy, Other

Session: Pharmacology and Pharmacotherapy

Access
Like
Thumbnail

Safety, pharmacodynamic and pharmacokinetic characterisation of vericiguat: key results from six phase I studies in healthy subjects

Event: Heart Failure 2019

Topic: Cardiovascular Pharmacotherapy, Other

Session: Pharmacology and Pharmacotherapy

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources